What is Ketamir?

A Novel Oral Ketamine Analog

Ketamir-2 (“Ketamir”) is under investigation to potentially orally deliver ultra-rapid antidepressant effects for patients who have not had a meaningful response to conventional treatments, providing new hope for individuals battling treatment-resistant depression (TRD) and major depressive disorder with suicidal ideation (MDSI).

Rapidly Acting Antidepressant

In the past decade, ketamine has shown to be a first in class rapidly acting medication for depression, showing effects in as early as 4 hours rather than 1 – 2 weeks like conventional antidepressants

Superior Bioavailability

Oral bioavailability is predicted to be 80% based on a model of intestinal absorption and metabolism.

More Accessibility

Ketamir is being developed to potentially be delivered at home with appropriate conditions.


Its novel structure and properties are different from existing Ketamine.


After making its scientific review of Ketamir, the DEA concluded that Ketamir-2 is not a controlled substance or listed chemical under the Controlled Substances Act (CSA) and its governing regulations.

Our Research

Find out more about our research featuring Ketamir.

View Our Research & Publications